Chile - Tiếng Tây Ban Nha - ISPC (Instituto de Salud Pública de Chile)

novartis chile s.a. - darunavir - sin formulas

Liên Minh Châu Âu - Tiếng Tây Ban Nha - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - infecciones por vih - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta, está indicado en combinación con otros medicamentos antirretrovirales para el tratamiento de la infección por el virus de la inmunodeficiencia humana 1 (vih 1) en adultos de 18 años o más. el análisis genotípico deben guiar el uso de rezolsta.

Liên Minh Châu Âu - Tiếng Tây Ban Nha - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infecciones por vih - antivirales para uso sistémico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Chile - Tiếng Tây Ban Nha - ISPC (Instituto de Salud Pública de Chile)

siron pharma s.p.a. - darunavir - sin formulas

Chile - Tiếng Tây Ban Nha - ISPC (Instituto de Salud Pública de Chile)

siron pharma s.p.a. - darunavir - sin formulas

Liên Minh Châu Âu - Tiếng Tây Ban Nha - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, cobicistat, emtricitabina, tenofovir alafenamide - infecciones por vih - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza está indicado para el tratamiento de la infección por el virus de inmunodeficiencia humana tipo 1 (vih-1) en adultos y adolescentes (a partir de 12 años con un peso corporal de al menos 40 kg). genotypic testing should guide the use of symtuza.

Ecuador - Tiếng Tây Ban Nha - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

iora lifecare pvt ltd india - darunavir 600 mg - tableta recubierta - cada tableta recubierta contiene: darunavir etanolato 650.472 mg (equivalente a 600 mg de darunavir)

Ecuador - Tiếng Tây Ban Nha - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

iora lifecare pvt ltd india - darunavir 300 mg - tableta recubierta - cada tableta recubierta contiene: darunavir etanolato 325.236 mg (equivalente a 300 mg de darunavir)

Ecuador - Tiếng Tây Ban Nha - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

pharmanovelty s.a. costa rica - darunavir 600 mg - tableta recubierta - cada tableta recubierta contiene: darunavir etanolato * 650,460 mg * equivalente a darunavir 600 mg

Ecuador - Tiếng Tây Ban Nha - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

hetero labs limited india - darunavir (amorfo)* 600.000 mg - comprimidos recubiertos - cada comprimido recubierto contiene: darunavir (amorfo)* 600.000 mg